Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben‐Quan Shen(Snap (United States)), Jagath R. Junutula(Chrono Therapeutics (United States)), Helga Raab, Kathryn Parsons-Reponte(Snap (United States)), Luna Liu(Snap (United States)), Shang‐Fan Yu(Genesys (United States)), Reina N. Fuji, Leslie A. Khawli(Target (United States)), Keyang Xu(Macau University of Science and Technology), Elaine Mai(Snap (United States)), Susan D. Spencer, Jay Tibbitts(Snap (United States)), Philip E. Hass(Snap (United States)), Kelly M. Flagella(Unknown), Trung Van Nguyen(Snap (United States)), Charles Eigenbrot(Unknown), Paul Polakis(Intarcia Therapeutics (United States)), Sunil Bhakta(Intarcia Therapeutics (United States)), Paul J McDonald(Snap (United States)), Margaret Kenrick(Snap (United States)), Allen Ebens(Unknown), Janet Tien(Snap (United States)), Jakub Baudys(Snap (United States)), Suzie J. Scales(Unknown), Willy A. Solis(Snap (United States)), Dongwei Li(Snap (United States)), Darshana Patel(Snap (United States)), Richard H. Scheller(Howard Hughes Medical Institute), Surinder Kaur(University of Bristol), Wai Lee Wong, Richard Vandlen(PDL BioPharma (United States)), Mark X. Sliwkowski(Molecular Oncology (United States)), Ola M. Saad(Snap (United States))
Cited by 997
Related Papers
Wnt signaling and cancer
|Genes & Development|2000|3.2k
SNAREs — engines for membrane fusion
|Nature Reviews Molecular Cell Biology|2006|2.6k
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
|Nature Biotechnology|2008|1.4k